glp glucagon like peptide Glucagon-like peptide-1 receptor agonists (GLP-1s or GLP-1RAs - Glp1 agonists GLP-1 inhibits food intake and promotes satiety Understanding Glucagon-Like Peptide-1 (GLP-1) and Its Therapeutic Applications

Glp1 agonists Glucagon-like peptide-1 (GLP-1) is a fascinating and increasingly vital hormone that plays a significant role in human physiology, particularly in regulating blood sugar and appetite.作者：JJ Holst·2007·被引用次数：4309—The main actions of GLP-1 areto stimulate insulin secretion(i.e., to act as an incretin hormone) and to inhibit glucagon secretion, thereby contributing to ... This naturally occurring peptide, produced in the small intestine after food intake, has garnered considerable attention for its therapeutic potential, leading to the development of GLP-1 agonists and GLP-1 receptor agonists (GLP-1RAs). These medications mimic the actions of the natural glucagon-like peptide, offering promising treatment options for conditions like type 2 diabetes and obesity.

The Physiology of Glucagon-Like Peptide-1 (GLP-1)

At its core, glucagon-like peptide-1 (GLP-1) is a 30- or 31-amino-acid-long peptide hormone derived from the post-translational processing of proglucagon. It functions as an incretin hormone, meaning it is released from the gut in response to food consumption and enhances glucose-dependent insulin secretionGLP-1 Agonists. The primary actions of GLP-1 are to stimulate insulin secretion from the pancreas and to inhibit glucagon secretion, a hormone that raises blood sugar levels.Glucagon-like peptide 1is a hormone produced in the gut and released in response to food. It causes reduced appetite and the release of insulin. This dual action effectively helps to regulate blood sugar levels, preventing them from rising too high after a meal.

Beyond its effects on glucose metabolism, GLP-1 also exerts significant influence on appetite and satiety. It is known to inhibit food intake and promote satiety, contributing to a feeling of fullnessDiscovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP .... This effect is crucial in understanding its role in weight management.作者：K Dungan·被引用次数：38—This topic will review the mechanism of action and therapeutic utility ofGLP-1-based therapies for the treatment of type 2 diabetes mellitus. The hormone signals to the brain, reducing hunger and thereby influencing consumer food purchases and overall dietary habits.

Therapeutic Applications of GLP-1 Receptor Agonists

The understanding of GLP-1's physiological functions has paved the way for the development of a class of medications known as glucagon-like peptide-1 receptor agonists (GLP-1RAs), also referred to as GLP-1 drugs, also called GLP-1 agonists, or GLP-1 analogs. These GLP-1 agonists are a class of medications designed to mimic the effects of the natural hormone. GLP-1 RAs work by imitating the natural hormone GLP-1 to lower blood glucose by stimulating insulin production and reducing glucagon release.

These GLP-1-based therapies for the treatment of type 2 diabetes mellitus have become increasingly prominent. By improving glycemic control, they offer a valuable tool for managing this chronic condition.作者：L Collins·2024·被引用次数：337—Glucagon-like peptide-1 (GLP-1) agonistsare a class of medications utilized to treat type 2 diabetes mellitus (T2DM) and obesity. Furthermore, due to their impact on appetite and satiety, GLP-1 receptor agonists (GLP-1s or GLP-1RAs) are increasingly used for type 2 diabetes and obesity treatment. The ability of these medications to help individuals feel fuller for longer can lead to reduced calorie intake and subsequent weight loss, making them a significant advancement in obesity management.

Several specific medications fall under the umbrella of GLP-1 receptor agonists. For instance, Liraglutide is an acylated glucagon-like peptide-1 (GLP-1) analogue that has been approved for daily use.Consumer Food Purchases After Glucagon-Like Peptide-1 ... Other research continues to explore novel compounds, such as Retatrutide (LY3437943), which acts as an agonist for multiple receptors, including the glucagon-like peptide 1 and glucagon receptors, showing significant promise in treating obesity.

Understanding the Nuances and Considerations

While the benefits of GLP-1 receptor agonists are substantial, it's important to acknowledge potential considerations. The U[Updated] Glucagon-like Peptide-1 (GLP-1) Receptor ....S. Food and Drug Administration (FDA) has issued warnings regarding unapproved versions of GLP-1. It is crucial for patients and healthcare professionals to be aware of and utilize only approved and regulated medications to ensure safety and efficacy作者：A Jakubowska·2024·被引用次数：45—GLP-1 inhibits food intake and promotes satietyin healthy individuals and those with obesity and diabetes..

The field of GLP-1 research is dynamic, with ongoing investigations into its multifaceted roles and potential applications.Triple–Hormone-Receptor Agonist Retatrutide for Obesity The development of GLP-1 mimics represents a significant breakthrough, providing some of the first truly effective medications for treating obesity. While the primary focus has been on managing type 2 diabetes and obesity, the broader implications of GLP-1 on metabolic health continue to be explored.作者：J Lau·2015·被引用次数：1121—Liraglutide is an acylated glucagon-like peptide-1 (GLP-1) analogue that binds to serum albumin in vivo and is approved for once-daily ...

In summary, glucagon-like peptide-1 (GLP-1) is a critical hormone with profound effects on glucose homeostasis and appetite regulation. The advent of GLP-1 receptor agonists has revolutionized treatment approaches for type 2 diabetes and obesity, offering a new avenue for improving patient outcomes. As research progresses, our understanding of this remarkable peptide and its therapeutic potential will undoubtedly continue to expand.Glucagon-like peptide-1 receptor: mechanisms and ...